Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › Phase III TG103 + metformin vs dulaglutide (EASD 2026)

Phase III TG103 + metformin vs dulaglutide (EASD 2026)

TG103 · t2d

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
TG103
Population
t2d
Phase
3
Participants
211
Duration
52 weeks

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
15 mg QW vs dulaglutide 1.5 mg QW (active comparator): HbA1c -1.25t2d china52211——−1.3——————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (1)
  • 15 mg QW · hba1c · HKEX filing
    Injection 15 mg group was higher than that in the dulaglutide 1.5 mg group (1.31% vs 1.25%),

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: Phase III TG103 + metformin vs dulaglutide (EASD 2026). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-iii-tg103-metformin-vs-dulaglutide/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.